DDInter1033 DDInter1435
Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Leflunomide {u} (Compound) resembles {v} (Compound) Niflumic Acid
Leflunomide {u} (Compound) treats {v} (Disease) systemic scleroderma
Leflunomide {u} (Compound) binds {v} (Gene) PTK2B
Leflunomide {u} (Compound) upregulates {v} (Gene) WIF1
Leflunomide {u} (Compound) downregulates {v} (Gene) MRPS16
Leflunomide {u} (Compound) causes {v} (Side Effect) Skin nodule
Leflunomide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Leflunomide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Leflunomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clostridium tetani toxoid antigen (formaldehyde inactivated)
Leflunomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Losartan
Leflunomide (Compound) resembles Niflumic Acid (Compound)
Leflunomide (Compound) treats systemic scleroderma (Disease)
Leflunomide (Compound) binds PTK2B (Gene)
Leflunomide (Compound) upregulates WIF1 (Gene)
Leflunomide (Compound) downregulates MRPS16 (Gene)
Leflunomide (Compound) causes Skin nodule (Side Effect)
Leflunomide may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Leflunomide may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Losartan